RedHill Biopharma (RDHL) Commences YELIVA Phase 1b/2 in r/r/ Multiple Myeloma
Tweet Send to a Friend
RedHill Biopharma Ltd. (Nasdaq: RDHL) announced that a Phase Ib/II clinical study evaluating YELIVA (ABC294640) in patients with refractory or ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
